N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells.

C. Beuneu, O. Vosters, Z. Ling, D. Pipeleers, O. Pradier, M. Goldman, V. Verhasselt

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

AIMS/HYPOTHESIS: The early loss of beta cells after islet cell transplantation has been attributed in part to blood coagulation at the implant site. Tissue factor expressed by beta cells and contaminating duct cells is considered to activate this process. Here, we investigated the ability of N-acetyl-L-cysteine to suppress the in vitro procoagulant activity of duct cells and human islet cell preparations. MATERIALS AND METHODS: The effects of Nacystelyn, a salt derivative of N-acetyl-L-cysteine, were first assessed on procoagulant activity induced in human plasma by recombinant tissue factor, human primary duct cells or human islet cell preparations. The influence of Nacystelyn on clot formation, platelet counts and D-dimers were measured in a whole blood tubing loop model. Human beta cell viability and insulin synthesis after Nacystelyn treatment were assessed to exclude cytotoxicity of Nacystelyn. RESULTS: Nacystelyn efficiently inhibited the procoagulant activity of human recombinant tissue factor, primary duct cells and human islet cell preparations at clinically relevant concentrations without cellular toxicity. CONCLUSIONS/INTERPRETATION: Nacystelyn is a pharmaceutical candidate to reduce early beta cell loss related to tissue factor-dependent coagulation after islet transplantation.

Original languageEnglish
Pages (from-to)343-347
Number of pages5
JournalDiabetologia
Volume50
Issue number2
DOIs
Publication statusPublished - 1 Feb 2007
Externally publishedYes

Fingerprint Dive into the research topics of 'N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells.'. Together they form a unique fingerprint.

Cite this